Further, Should they look at Covid ARDS Trial results and decide well there was some effect maybe more pronounced earlier in trial, might their response be, lets do another 12 patient study immediately with say dosing tied to Biomarkers, to see if bigger trial warranted?
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-179
-
- There are more pages in this discussion • 245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.000(0.00%) |
Mkt cap ! $1.370B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.18 | $2.465M | 2.064M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 17854 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 12689 | 8 |
View Market Depth
| Last trade - 11.36am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |